EA
EBS icon

Emerald Acquisition’s Emergent Biosolutions EBS Stock Holding History

Emerald Acquisition’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$13.6M Sell
429,845
-42,382
-9% -$1.23M 0.03% 708
2016
Q2 		$13.3M Buy
+472,227
New +$18.5M 0.02% 787

Other funds holding EBS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AAM
Aberdeen Asset Management Aberdeen, United Kingdom $30B AUM 22.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Emerald Acquisition's EBS Position: Q3 2016 in Review

Emerald Acquisition reduced its Emergent Biosolutions (EBS) stake by 9% in Q3 2016, selling an estimated $1.23M and leaving 429,845 shares worth $13.6M. The position accounts for 0.03% of the portfolio, ranked #708.

Emerald Acquisition first reported a position in EBS in Q2 2016 and has held it in 2 quarters since. 203 funds tracked by Wall St. Rank hold EBS as of Q3 2016.

  • Emerald Acquisition held 429,845 shares of Emergent Biosolutions worth $13.6M as of Q3 2016.
  • Emerald Acquisition sold 42,382 Emergent Biosolutions shares in Q3 2016, an estimated $1.23M.
  • Emergent Biosolutions made up 0.03% of Emerald Acquisition's portfolio in Q3 2016, its #708 holding.
  • Emerald Acquisition first reported a position in Emergent Biosolutions in Q2 2016 and has held it in 2 quarters since.
  • 203 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.